Bexarotene is a retinoid drug used for cutaneous manifestations of T-cell lymphoma in patients who have not responded well to previous systemic therapy. Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma.
- Mechanism
- Curator reviewed
Bexarotene selectively binds with and activates retinoid X receptor subtypes. There are three subtypes in total: RXRα, RXRβ, RXRγ. The exact mechanism of action of bexarotene in the treatment of CTCL is unknown but the drug has activity in all clinical stages of CTCL.
- Primary indication
- Used orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy.Curator reviewed · 2 structured indications
- Formula / weight
- C24H28O2 · 348.4779 g/mol (avg)
- First approval
- United States, 1999 · European Union, 2016
- Code names
- LG-100069 · LGD-1069
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
NAVMQTYZDKMPEU-UHFFFAOYSA-NSMILESCC1=CC2=C(C=C1C(=C)C1=CC=C(C=C1)C(O)=O)C(C)(C)CCC2(C)CWhat you can answer from here — as of September 13, 2026
4Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Bexarotene, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account